Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2011-08-23
2011-08-23
Ewoldt, G. R. (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
08003331
ABSTRACT:
A method for identifying a target protein of a compound having a pharmacological action by detecting a tertiary structural change of a target protein by binding a compound having a pharmacological action to a target protein with the use of a molecular chaperone protein having a characteristic of binding to a protein by recognizing a tertiary structural change of the protein is disclosed. Further, a method for screening a therapeutic agent for diabetes using a target protein of biguanide which is a therapeutic agent for diabetes and was found by the identification method, a screening tool which can be used in the screening method and a pharmaceutical composition for treating diabetes containing a substance obtained by the screening method are disclosed.
REFERENCES:
patent: 5585277 (1996-12-01), Bowie et al.
patent: 5679582 (1997-10-01), Bowie et al.
patent: 6207401 (2001-03-01), Plowman et al.
patent: 6579868 (2003-06-01), Asano et al.
patent: 6790958 (2004-09-01), Lum et al.
patent: 7244577 (2007-07-01), Todd et al.
patent: 2002/0055123 (2002-05-01), Pakula et al.
patent: 2004/0072368 (2004-04-01), Martinez
patent: 2004/0191835 (2004-09-01), Pakula et al.
Lazar, E., et al. Mol. Cell Biol. 1988;8(3):1247-1252.
Burgess, W.H., et al. J. Cell Biol. 1990;111:2129-2138.
Parakhia, R.A., et al. Faseb J. 2009; 23(1):856.16.
Foretz, M., et al. J. Clin. Invest. 2010;120(7):2355-2369.
Hatori, H., et al., “FR225659-binding Proteins: Identification as Serine/Threonine Protein Phosphatase PP1 and PP2A Using High-performance Affinity Beads,”The Journal of Antibiotics,vol. 57, No. 7, Jul. 2004, pp. 456-461.
Teo, S.K., et al., “Thalidomide as a novel therapeutic agent: new uses for an old product,”Drug Discovery Today,vol. 10, No. 2, Jan. 2005, pp. 107-114.
Lalau, J.D., et al., “Lactic Acidosis in Metformin Therapy,”Drugs,vol. 58, Suppl. 1, 1999, pp. 55-60 and pp. 75-82.
Shimizu, N., et al., “High-performance affinity beads for identifying drug receptors,”Nature Biotechnology(England), vol. 18, Aug. 2000, pp. 877-881.
Henthorn, D.C., et al., “A GAL-4 based yeast three-hybrid system for the identification of small molecule-target protein interactions,”Biochemical Pharmacology,vol. 63, 2002, pp. 1619-1628.
Sche, P.P., et al., “Display clonging: functional identification of natural product receptors using cDNA-phage display,”Chemistry&Biology,vol. 6, No. 10, 1999, pp. 707-716.
Lehmann, J.M., et al., An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)*,The Journal of Biological Chemistry(USA), vol. 270, No. 22, Jun. 2, 1995, pp. 12953-12956.
Noji, H., et al., “Direct observation of the rotation of F1-ATPase,”Nature(USA), vol. 386, Mar. 20, 1997, pp. 299-302.
Abrahams, J.P., et al., “Structure at 2.8 Å resolution of F1-ATPase from bovine heart mitochondria,”Nature(USA), vol. 370, Aug. 25, 1994, pp. 621-628.
Gething et al., “Protein folding in the cell,” Nature, vol. 355, Jan. 2, 1992, pp. 33-45.
Højlund et al., “Proteome Analysis Reveals Phosphorylation of ATP Synthase β-Subunit in Human Skeletal Muscle and Proteins with Potential roles in Type 2 Diabetes,” J. Biological Chemistry, vol. 278, No. 12, Mar. 21, 2003, pp. 10436-10442.
Schäfer, “Some New Aspects on the Interaction of Hypoglycemia-Producing Biguanides with Biological Membranes,” Biochemical Pharmacology, vol. 25, No. 18 (1976) pp. 2015-2024.
Sreedhar et al., “Heat shock proteins in the regulation of apoptosis:new strategies in tumor therapy A comprehensive review,” Pharmacology & Therapeutics, vol. 101, No. 3, (2004) pp. 227-257.
Sreekumar et al., “Gene Expression Profile in Skeletal Muscle of Type 2 Diabetes and the Effect of Insulin Treatment, Diabetes,” vol. 51, Jun. 2002, pp. 1913-1920.
Beliakoff, J., et al., “Hormone-Refractory Breast Cancer Remains Sensitive to the Antitumor Activity of Heat Shock Protein 90 Inhibitors”, Clinical Cancer Research, Oct. 2003, pp. 4961-4971, vol. 9., No. 13, American Association for Cancer Research, XP002548503.
Rosenhagen, M., “The Heat Shock Protein 90-Targeting Drug Cisplatin Selectively Inhibits Steroid Receptor Activation”, Molecular Endocrinology, Oct. 2003, pp. 1991-2001, vol. 17, No. 10, The Endochrine Society, XP002548504.
Tateishi, Y., et al., “Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor”, The EMBO Journal, Dec. 2004, pp. 4813-4823, vol. 23, No. 24, European Molecular Biology Organization, XP002548505.
European Office Action in corresponding European Application No. 09075347.6, issued Jun. 23, 2010, European Patent Office.
Endoh Hideki
Hayakawa Masahiko
Soga Shinji
Yokota Hiroyuki
Astellas Pharma Inc.
Ewoldt G. R.
Sughrue & Mion, PLLC
LandOfFree
Method for identifying target protein of drug and method for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for identifying target protein of drug and method for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for identifying target protein of drug and method for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2747024